Recent news on Palonosetron

MGI Pharma and Helsinn Announce Submission of Supplemental New ...  -  May 7, 2007
PharmaLive.com (press release),HELSINN HEALTHCARE SA, a privately owned pharmaceutical group with headquarters in Switzerland, is the worldwide licensor of palonosetron.

MGI Pharma First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI PHARMA Reports First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),During the first quarter of 2007, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $47.3 million compared to $63.3 million in the first

HELSINN HEALTHCARE SA Announces Patent Extension for Aloxi(R ...  -  Feb 13, 2007
netPR.pl (komunikaty prasowe),Helsinn HEALTHCARE SA is a privately owned pharmaceutical group with headquarters in Switzerland and is the worldwide licensor of palonosetron.

HELSINN HEALTHCARE SA Announces Patent Extension for Aloxi(R ...  -  Feb 13, 2007
Earthtimes.org...patent term extensionhas been granted by the US Patent and Trademark Office for the patentcovering Aloxi(R) (palonosetron hydrochloride) Injection.

MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 8, 2007
PharmaLive.com (press release),During the fourth quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $49.6 million compared to $67.0 million in the fourth

MGI Pharma to Present at the 2007 Merrill Lynch Global ...  -  Feb 1, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA to Present at the 2007 Merrill Lynch Global ...  -  Jan 31, 2007
dBusinessNews Minneapolis (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI Pharma Announces Publication of Phase 3 Data for Saforis ...  -  18 Jan 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

JPMorgan 25th Annual Healthcare Conference  -  18 Jan 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

Biovitrum Launches New Drug in Nordic Countries Against Nausea ...  -  Jan 8, 2007
PharmaLive.com (press release),...against nausea caused by chemotherapy: Aloxi(R) (palonosetron), administered in the form of an injection prior to the initiation of chemotherapy.

MGI Pharma Announces Publication of Phase 2 Data Describing ...  -  Jan 3, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

AP Pharma Resets APF530 NDA Filing Expectations  -  Dec 22, 2006
PipelineReview.com (press release),...be treated with APF530, high and low dose form and a third arm will be treated with the currently approved dose of palonosetron (brand name ALOXI(R)).

Helsinn Announces Positive Phase 3 Results for Aloxi(R ...  -  Dec 14, 2006
Drug Newswire (press release),Helsinn Healthcare SA is a privately owned pharmaceutical group with headquarters in Switzerland and is the worldwide licensor of palonosetron.

Helsinn Announces Positive Phase 3 Results for Aloxi(R ...  -  Dec 14, 2006
Earthtimes.org...completion of two phase 3 trials ofAloxi(R) (palonosetron hydrochloride) Injection for the prevention ofpost-operative nausea and vomiting (PONV).

MGI to File for New Aloxi Use in 2007  -  Dec 14, 2006
Houston Chronicle,...million to $350 million in revenue for the year. Switzerland-based Helsinn holds the worldwide license for palonosetron, the active ingredient in Aloxi.

Market Report -- In Play (MOGN)  -  Dec 14, 2006
MSN Money...successful completion of two phase 3 trials of Aloxi (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting.

AP Pharma Resets APF530 NDA Filing Expectations  -  Dec 22, 2006
PipelineReview.com (press release),...be treated with APF530, high and low dose form and a third arm will be treated with the currently approved dose of palonosetron (brand name ALOXI(R)).

(PRN) - Bowlin Travel Centers Report Nine-Month and Third Quarter ...  -  Dec 14, 2006
Bolsamania.com,...(PRN) - Helsinn Announces Positive Phase 3 Results for Aloxi(R)(Palonosetron Hydrochloride) Injection for the Prevention of Post Operative Nausea & Vomiting

AP Pharma Reports 2006 Third Quarter Results  Nov 7, 2006
...each; two arms will be treated with APF530, high and low dose form and a third arm will be treated with the currently approved dose of palonosetron (brand name ... -PharmaLive.com (press release), MGI PHARMA Recognized for Innovation & Growth  Nov 2, 2006
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogenâ„¢ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine ... -Business Wire (press release), MGI PHARMA Recognized for Innovation & Growth  Nov 2, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -Genetic Engineering News (press release), MGI PHARMA Reports Third Quarter 2006 Financial Results  Oct 18, 2006
...in the third quarter of 2006 from $66.4 million in the third quarter of 2005, driven primarily by higher sales of Aloxi® (palonosetron hydrochloride) Injection ... -Business Wire (press release), MGI PHARMA to Present at the UBS Global Life Sciences Conference  Sep 19, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -Business Wire

MGI PHARMA to Present at the Lazard Capital Markets Third Annual ...  -  Nov 20, 2006
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI Pharma to Present at the Lazard Capital Markets Third Annual ...  -  Nov 21, 2006
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

AP Pharma Reports 2006 Second Quarter Results; Phase 3 Clinical ...  Aug 8, 2006
...two arms will be treated with APF530, high and low dose form, and a third arm will be treated with the currently approved dose of palonosetron (brand name ALOXI ... -Business Wire

MGI PHARMA Announces Executive Appointments  Aug 8, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -dBusinessNews Minneapolis

MGI PHARMA Reports Second Quarter 2006 Financial Results  Jul 19, 2006
...the second quarter of 2006 from $65.3 million in the second quarter of 2005, driven primarily by higher sales of Aloxi(R) (palonosetron hydrochloride) Injection ... -Business Wire

MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25 ...  Jul 19, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -Business Wire

MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson ...  Jul 6, 2006
MGIPHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection,Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer(polifeprosan 20 with carmustine ... -Finanzen.net



AP Pharma Reports 2006 First Quarter Results; Phase 3 Clinical ...  May 10, 2006
...each; two arms will be treated with APF530, high and low dose form and a third arm will be treated with the currently approved dose of palonosetron (brand name ... - Genetic Engineering News

AbelsonTaylor Announces Four New Appointments  May 11, 2006
Laura Dodd, newly hired senior copywriter, will manage projects for Aloxi (palonosetron HCL injection), a drug for treating adverse effects of chemotherapy ... - PharmaLive.com

MGI PHARMA to Present at the 2006 Bank of America Health Care ...  May 11, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com

US FDA Approves Dacogen(TM) (Decitabine) For Injection  May 3, 2006
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States, and ... - Yahoo! News

US FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM ...  May 3, 2006
MGI PHARMAmarkets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R)Wafer (polifeprosan 20 with carmustine implant) in the United States,and ... - Finanzen.net

MGI PHARMA Announces Publication of Phase 3 Data for Dacogen ...  Apr 18, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com

MGI PHARMA Reports First Quarter 2006 Financial Results; First ...  Apr 19, 2006
During the first quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $63.3 million compared to $57.2 million in the first ... - Business Wire





Helsinn and Pfizer sign a license agreement for the marketing of ...  Apr 6, 2006
Pty), Ltd., announced the signing of an agreement granting Pfizer the exclusive license and distribution rights of Aloxi (Palonosetron hydrochloride), a ... - Therapeutics Daily (subscription)

AP Pharma Reports 2005 Full Year and Fourth Quarter Results ...  Mar 15, 2006
Agency in order to initiate a single pivotal Phase 3 clinical trial, which will compare the safety and efficacy of APF530 with palonosetron, currently marketed ... - Business Wire

MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal ...  Mar 20, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News

Helsinn and Pfizer Laboratories (Pty) Ltd Sign a License Agreement ...  Mar 9, 2006
...announce the signing of an agreement granting Pfizer in South Africa, the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride), a ... - PR Newswire UK

ΞΕÎ?Η ΔΗΜΟΣΙΕΥΣΗ-ΑÎ?ΑΚΟΙÎ?ΩΣΗ ΤΥΠΟΥ -PRN ...  Mar 9, 2006
...announce the signing of an agreement granting Pfizer in South Africa, the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride), a ... - Athens News Agency



Helsinn and Biovitrum Enter a License Agreement for Nordic ...  Feb 15, 2006
AB, Sweden announce the signing of an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride) in ... - Genetic Engineering News,

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ...  Feb 9, 2006
...company, today announced that total revenue for 2005 increased 43% to $279.4 million, including Aloxi(R) (palonosetron hydrochloride) injection sales of $248.5 ... - Genetic Engineering News,

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ...  Feb 9, 2006
...biopharmaceutical company, today announced that totalrevenue for 2005 increased 43% to $279.4 million, including Aloxi(R)(palonosetron hydrochloride) injection ... - Finanzen.net,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional